Efficacy of DMARDs Therapy on the Disease Activity and Gene Expression Levels of FoxO1, FoxO3, Runx1, and Runx3 in Early Rheumatoid Arthritis Patients: A Pre-Post Interventional Study With Healthy Controls. Journal Abstract - Guideline Central

Efficacy of DMARDs Therapy on the Disease Activity and Gene Expression Levels of FoxO1, FoxO3, Runx1, and Runx3 in Early Rheumatoid Arthritis Patients: A Pre-Post Interventional Study With Healthy Controls.

Published: 2025 Oct

Authors

, , , , , , , , , , ,

Abstract

Forkhead box O (FoxO) transcription factors exert crucial roles in immune responses. Besides, the Runt-related transcription factor (Runx) family plays a pivotal role in the development and homeostasis of cartilage and bone. This study assessed the plasma concentrations of the pro-inflammatory interleukin-6 (IL-6) cytokine and the anti-inflammatory cytokine interleukin-10 (IL-10), as well as the gene expression levels of FoxO1, FoxO3, Runx1, and Runx3, in the peripheral blood sample of the early rheumatoid arthritis (RA) patients treated with conventional disease-modifying antirheumatic drugs (DMARDs) for 6 months relative to normal subjects.

Keywords: Runx3, disease activity, forkhead box O3, interleukin‐6, rheumatoid arthritis

Source

Health science reports

Publication Type

Journal Article

Language

English

PubMed ID

41132193

You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.